Literature DB >> 10896238

Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease.

A Günther1, P Mosavi, C Ruppert, S Heinemann, B Temmesfeld, H G Velcovsky, H Morr, F Grimminger, D Walmrath, W Seeger.   

Abstract

Bronchoalveolar lavage fluids (BALF) from patients with hypersensitivity pneumonitis (HP; n = 35), idiopathic pulmonary fibrosis (IPF, n = 41) and sarcoidosis (SARC, n = 48) were investigated for alterations in the alveolar hemostatic balance. Healthy individuals (n = 21) served as Controls. Procoagulant activity (PCA), tissue factor (TF) activity and F VII activity were assessed by means of specific recalcification assays. The overall fibrinolytic activity (FA) was measured using the (125)I-labeled fibrin plate assay. Fibrinopeptide A (FP-A), D-Dimer, plasminogen activators (PA) of the urokinase (u-PA) or tissue type (t-PA), PA-inhibitor I (PAI-1) and alpha2-antiplasmin (alpha2-AP) were determined by ELISA technique. As compared to Controls, all groups with interstitial lung disease (ILD) displayed an increase in BALF PCA by approximately one order of magnitude, and this was ascribed to enhanced TF activity by >98%. Accordingly, F VII-activity was increased in all ILD groups, and elevated FP-A levels were noted. There was no significant difference in procoagulant activities between the different ILD entities, but the increase in TF was significantly correlated with deterioration of lung compliance. Overall fibrinolytic activity did not significantly differ between ILD entities and Controls, although some reduction in IPF subjects was observed. Nevertheless, changes in the profile of the different pro- and antifibrinolytic compounds were noted. U-PA, but not t-PA levels were significantly reduced in all ILD groups. alpha2-AP was markedly elevated throughout, whereas PAI-1 levels were lowered. As a balance of

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896238

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  26 in total

1.  Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis.

Authors:  Keren Borensztajn; Paul Bresser; Chris van der Loos; Ilze Bot; Bernt van den Blink; Michael A den Bakker; Joost Daalhuisen; Angelique P Groot; Maikel P Peppelenbosch; Jan H von der Thüsen; C Arnold Spek
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

Review 2.  Acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-06-21       Impact factor: 21.405

3.  Increased transforming growth factor beta 1 expression mediates ozone-induced airway fibrosis in mice.

Authors:  Ashwini Katre; Carol Ballinger; Hasina Akhter; Michelle Fanucchi; Dae-Kee Kim; Edward Postlethwait; Rui-Ming Liu
Journal:  Inhal Toxicol       Date:  2011-07       Impact factor: 2.724

4.  Is warfarin the right anticoagulant in idiopathic pulmonary fibrosis?

Authors:  Elisabeth Bendstrup; Ole Hilberg
Journal:  Am J Respir Crit Care Med       Date:  2012-10-01       Impact factor: 21.405

5.  Radiation induced pulmonary fibrosis as a model of progressive fibrosis: Contributions of DNA damage, inflammatory response and cellular senescence genes.

Authors:  Tyler A Beach; Carl J Johnston; Angela M Groves; Jacqueline P Williams; Jacob N Finkelstein
Journal:  Exp Lung Res       Date:  2017-05-23       Impact factor: 2.459

6.  Pharmacoproteomics reveal novel protective activity of bromodomain containing 4 inhibitors on vascular homeostasis in TLR3-mediated airway remodeling.

Authors:  Yingxin Zhao; Bing Tian; Hong Sun; Jing Zhang; Yueqing Zhang; Maxim Ivannikov; Massoud Motamedi; Zhiqing Liu; Jia Zhou; Lata Kaphalia; William J Calhoun; Rosario Maroto; Allan R Brasier
Journal:  J Proteomics       Date:  2019-06-10       Impact factor: 4.044

7.  Transforming growth factor-β1 induces expression of human coagulation factor XII via Smad3 and JNK signaling pathways in human lung fibroblasts.

Authors:  Ewa Jablonska; Philipp Markart; Dariusz Zakrzewicz; Klaus T Preissner; Malgorzata Wygrecka
Journal:  J Biol Chem       Date:  2010-02-08       Impact factor: 5.157

8.  Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study.

Authors:  Marcel Schouten; Koenraad F van der Sluijs; Bruce Gerlitz; Brian W Grinnell; Joris J T H Roelofs; Marcel M Levi; Cornelis van 't Veer; Tom van der Poll
Journal:  Crit Care       Date:  2010-04-14       Impact factor: 9.097

9.  4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia.

Authors:  Anil Sapru; Helen Hansen; Temitayo Ajayi; Ron Brown; Oscar Garcia; HanJing Zhuo; Joseph Wiemels; Michael A Matthay; Jeanine Wiener-Kronish
Journal:  Anesthesiology       Date:  2009-05       Impact factor: 7.892

Review 10.  Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis.

Authors:  Rui-Ming Liu
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.